Createmed published an article in Molecular Therapy-Nucleic Acids

The article titled "Intratumoral delivery of novel circular mRNA encoding cytokines for immune modulation and cancer therapy".

This study represents an early attempt by Createmed to engineer circular mRNA.

Based on the IRES of EcoRI29 and novel homologous arms and spacer sequences, this study created a novel circular mRNA, which was named "cmRNA".

Compared to classical linear mRNA, cmRNA can mediate higher expression levels of various types of proteins both in vitro and in vivo.

This article demonstrates for the first time the feasibility of direct intratumoral injection of circular mRNA, and investigates and optimizes formulations suitable for intratumoral injection of circular mRNA.

Intratumoral injection of cmRNA encoding multiple cytokines can significantly inhibit tumor growth and exhibits synergistic effects when combined with immune checkpoint inhibitors.

This is also the world's first research achievement in applying circular mRNA to the field of tumor treatment.

[Company Introduction]

Suzhou Kerui Maide Biopharmaceutical Technology Co., Ltd. is located on the 1st and 2nd floors of Building C, Tengfei Science and Technology Park, Suzhou Industrial Park.

A 4000㎡ laboratory that meets GMP standards has been established, and a 10000㎡ GMP production plant and R&D platform are currently under construction. 

Curemed focuses on the research and development of a new generation of circular mRNA nucleic acid drugs, and has applied for more than 30 core platform technology invention patents in the field of circular mRNA,

Multiple PCT international patents and 2 software copyrights.

The Clean-PIE system, a novel cyclization framework independently developed by Curemed, achieves precise and efficient cyclization without the introduction of exogenous sequences, boasts lower immunogenicity, and offers higher expression efficiency and duration.

We have developed the LNP nucleic acid delivery system with independent intellectual property rights, obtained the core patent authorization, and achieved mass production of LNP nucleic acid drugs.

The circular mRNA technology with independent intellectual property rights is domestically leading and internationally comparable.

Curemed aims to build a comprehensive circular mRNA nucleic acid pharmaceutical platform,

Actively develop product pipelines for infectious diseases, tumor immunology, protein replacement, gene therapy, cell therapy, and other fields,

To meet the huge clinical treatment needs.

Currently, we are actively promoting the IND application for our circular mRNA drug.